We all knew the initial mj card rush would slow after the q3, it was no secret. They have refined the model and keep moving forward. That said, it's nice to see ARtCA off the ask. Trading retail now. Still sellers, but the move is coming and will be much easier without the extra shares.
Some people play stocks and move on, some apparently play them, make money, then talk bad about them. It's OTC magic.
Whether they are locking down corporate ownership of the PAOG offering or buying out more successful clinics it's good news for investors.
Not sure that comparing 2017 Q3 to Q4 is the best metric for evaluating PAOGs strength. I'd say a far more telling metric is to compare 2016 revs to 2017 revs.
2016 $0 revs 2017 $417k revs
I'd say that and the activity of Q1 2018 is far more telling of the overall trend here.
News 
Market Data 
Discover 
